Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Purpose
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Conditions
- Metastatic Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Unresectable Renal Cell Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma prior to registration - Node-positive unresectable (TxN1Mx) or metastatic (TxNxM1) based on the following diagnostic workup: - History/physical examination within 45 days prior to registration - CT/magnetic resonance imaging (MRI) of the chest/abdomen/pelvis within 45 days prior to registration - Patients must have IMDC intermediate (1-2 factors) or poor risk disease (>= 3 factors) - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with measurable disease (node positive or metastatic) as defined by RECIST version 1.1 excluding the primary renal tumor - Patient not recommended for or refused immediate cytoreductive nephrectomy - Candidate for standard of care therapy with either immuno-oncology (IO)-IO or IO-VEGF combination regimen - Primary renal tumor measuring 20 cm or less in anterior to posterior dimension only on axial imaging - Age >= 18 - Karnofsky performance status >= 60 within 45 days prior to registration - Hemoglobin >= 8 g/dL (transfusions are allowed) (within 45 days prior to registration) - Platelet count >= 50,000/mm^3 (within 45 days prior to registration) - Absolute neutrophil count (ANC) >= 1500/mm^3 (within 45 days prior to registration) - Calculated (Calc.) creatinine clearance >= 30 mL/min (within 45 days prior to registration) - Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault Equation - For African American patients specifically whose renal function is not considered adequate by the formula above, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) should be used for calculating the related estimated glomerular filtration rate (GFR) with a correction factor for African American race creatinine clearance for trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered adequate - Total bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) (within 45 days prior to registration) - Aspartate aminotransferase and alanine aminotransferase (AST and ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if hepatic metastases present (within 45 days prior to registration) - Patients with known human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Testing is not required for entry into protocol - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load - The patient must agree to use a highly effective contraception, including men with vasectomies if they are having sex with a woman of childbearing potential or with a woman who is pregnant, while on study drug and for 6 months following the last dose of study drug. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Patients with planned treatment of all metastatic disease with definitive therapy including either surgery, ablative (non-palliative) doses of radiation, or intervention of some type (definitive interventional radiology techniques) to ALL metastatic sites rendering the patient without extra-renal measurable disease. Patients NOT planned for definitive treatment of all metastatic sites are eligible. Lesions radiated palliatively are not eligible for response assessment - Patients with untreated or unstable brain metastases or cranial epidural disease - Note: Patients who have been adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks prior to registration as documented by MRI or CT imaging or deemed stable by clinical investigator are eligible. Treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 4 weeks prior to registration as documented by MRI or CT imaging or deemed stable by clinical investigator - Prior radiotherapy to the kidney that would result in overlap of radiation therapy fields treatment of the primary tumor - Any systemic therapy for metastatic renal cell carcinoma (RCC) that was initiated > 90 days before registration, note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration) - Severe, active comorbidity defined as follows: - Active autoimmune disease requiring ongoing therapy including systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications daily. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease - History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies - Active tuberculosis (purified protein derivative [PPD] response without active tuberculosis [TB] is allowed) - Uncontrolled hypertension (systolic blood pressure [BP] >= 190 mmHg or diastolic BP > 110 mmHg) - Major surgery requiring hospital admission =< 28 days prior to registration - Any serious (requiring hospital stay or long term rehab) non-healing wound, ulcer, or bone fracture within 45 days prior to registration - Any arterial thrombotic (ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], cerebrovascular accident [CVA], etc) events within 180 days prior to registration - Active New York (NY) Heart Association class 3-4 heart failure symptoms - Moderate or severe hepatic impairment (Child-Pugh B or C) - Any history of untreated pulmonary embolism or deep venous thrombosis (DVT) within 180 days prior to registration. (Any asymptomatic or treated pulmonary embolism or asymptomatic treated deep venous thrombosis > 30 days prior to registration is allowed) - Unstable cardiac arrhythmia within 180 days prior to registration - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 180 days prior to registration - History of or active inflammatory bowel disease - Malabsorption syndrome within 45 days prior to registration - Pregnancy and individuals unwilling to discontinue nursing. For women of child bearing potential must have a negative pregnancy test =< 45 days prior to registration
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (standard of care immunotherapy) |
Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib PO BID; avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO QD; OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. |
|
Experimental Arm II (SABR, standard of care immunotherapy) |
Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. |
|
Recruiting Locations
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Arroyo Grande 5324802, California 5332921 93420
Burlingame 5331920, California 5332921 94010
Encinitas 5346646, California 5332921 92024
Site Public Contact
760-536-7700
Irvine 5359777, California 5332921 92612
La Jolla 5363943, California 5332921 92093
Modesto 5373900, California 5332921 95355
Orange 5379513, California 5332921 92868
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95816
San Diego 5391811, California 5332921 92103
San Francisco 5391959, California 5332921 94158
San Mateo 5392423, California 5332921 94401
Santa Barbara 5392952, California 5332921 93105
Santa Rosa 5393287, California 5332921 95403
Aurora 5412347, Colorado 5417618 80045
Site Public Contact
720-848-0650
Denver 5419384, Colorado 5417618 80206
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Greeley 5577592, Colorado 5417618 80631
Highlands Ranch 5425043, Colorado 5417618 80129
Site Public Contact
720-848-0650
Lone Tree 5429208, Colorado 5417618 80124
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Aventura 4146429, Florida 4155751 33180
Hollywood 4158928, Florida 4155751 33021
Jacksonville 4160021, Florida 4155751 32224-9980
Site Public Contact
855-776-0015
Miami 4164138, Florida 4155751 33176
Site Public Contact
786-596-2000
Miami Beach 4164143, Florida 4155751 33140
Pembroke Pines 4168139, Florida 4155751 33028
Site Public Contact
954-265-4325
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-7323
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60611
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
312-695-1102
Grayslake 4894465, Illinois 4896861 60030
Site Public Contact
312-695-1102
Lake Forest 4899012, Illinois 4896861 60045
Mattoon 4244099, Illinois 4896861 61938
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Rockford 4907959, Illinois 4896861 61114
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Urbana 4914570, Illinois 4896861 61801
Warrenville 4915525, Illinois 4896861 60555
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
Baton Rouge 4315588, Louisiana 4331987 70809
Baton Rouge 4315588, Louisiana 4331987 70809
Metairie 4333177, Louisiana 4331987 70002
Site Public Contact
504-584-6990
Beverly 4930505, Massachusetts 6254926 01915
Site Public Contact
978-922-3000
Boston 4930956, Massachusetts 6254926 02114
Site Public Contact
877-726-5130
Boston 4930956, Massachusetts 6254926 02115
Site Public Contact
617-724-5200
Boston 4930956, Massachusetts 6254926 02215
Site Public Contact
877-442-3324
Burlington 4931737, Massachusetts 6254926 01805
Gloucester 4937829, Massachusetts 6254926 01930
Site Public Contact
978-283-4000
Peabody 4946863, Massachusetts 6254926 01960
Ann Arbor 4984247, Michigan 5001836 48106
Ann Arbor 4984247, Michigan 5001836 48109
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Dearborn 4990510, Michigan 5001836 48124
Site Public Contact
248-551-7695
Farmington Hills 4992523, Michigan 5001836 48336
Site Public Contact
248-551-7695
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Troy 5012639, Michigan 5001836 48085
Site Public Contact
248-551-7695
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Minneapolis 5037649, Minnesota 5037779 55415
Rochester 5043473, Minnesota 5037779 55905
Site Public Contact
855-776-0015
Saint Paul 5045360, Minnesota 5037779 55101
Sandstone 5045908, Minnesota 5037779 55072
Stillwater 5048814, Minnesota 5037779 55082
Virginia 5051468, Minnesota 5037779 55792
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Columbia 4381982, Missouri 4398678 65212
Site Public Contact
573-882-7440
Creve Coeur 4382837, Missouri 4398678 63141
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63136
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Basking Ridge 5095409, New Jersey 5101760 07920
Site Public Contact
212-639-7592
Camden 4501018, New Jersey 5101760 08103
Site Public Contact
856-325-6757
Lakewood 5100280, New Jersey 5101760 08701
Long Branch 5100619, New Jersey 5101760 07740
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
Mount Laurel 4503136, New Jersey 5101760 08054
New Brunswick 5101717, New Jersey 5101760 08903
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07101
Site Public Contact
732-235-7356
Toms River 4504476, New Jersey 5101760 08755
Albuquerque 5454711, New Mexico 5481136 87102
Albuquerque 5454711, New Mexico 5481136 87109
Commack 5113412, New York 5128638 11725
Site Public Contact
212-639-7592
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Harrison 5120095, New York 5128638 10604
Site Public Contact
212-639-7592
New York 5128581, New York 5128638 10016
New York 5128581, New York 5128638 10065
Site Public Contact
212-639-7592
Uniondale 5141927, New York 5128638 11553
Site Public Contact
212-639-7592
Chapel Hill 4460162, North Carolina 4482348 27599
Charlotte 4460243, North Carolina 4482348 28203
Site Public Contact
800-804-9376
Charlotte 4460243, North Carolina 4482348 28210
Site Public Contact
980-442-2000
Charlotte 4460243, North Carolina 4482348 28262
Site Public Contact
800-804-9376
Charlotte 4460243, North Carolina 4482348 28277
Site Public Contact
800-804-9376
Clemmons 4461015, North Carolina 4482348 27012
Site Public Contact
888-716-9259
Concord 4461574, North Carolina 4482348 28025
Site Public Contact
800-804-9376
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Gastonia 4467732, North Carolina 4482348 28054
Site Public Contact
800-804-9376
High Point 4471025, North Carolina 4482348 27262
Site Public Contact
336-802-2500
Monroe 4479946, North Carolina 4482348 28112
Site Public Contact
980-442-2000
Wilkesboro 4499138, North Carolina 4482348 28659
Site Public Contact
888-716-9253
Winston-Salem 4499612, North Carolina 4482348 27157
Site Public Contact
336-713-6771
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Avon 5146277, Ohio 5165418 44011
Site Public Contact
800-641-2422
Beachwood 5146711, Ohio 5165418 44122
Centerville 4508204, Ohio 5165418 45459
Centerville 4508204, Ohio 5165418 45459
Cincinnati 4508722, Ohio 5165418 45219
Cleveland 5150529, Ohio 5165418 44106
Columbus 4509177, Ohio 5165418 43210
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Dayton 4509884, Ohio 5165418 45415
Franklin 4512203, Ohio 5165418 45005-1066
Franklin 4512203, Ohio 5165418 45005
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Mentor 5162645, Ohio 5165418 44060
Parma 5166177, Ohio 5165418 44129
Ravenna 5167737, Ohio 5165418 44266
Troy 5174358, Ohio 5165418 45373
West Chester 4520522, Ohio 5165418 45069
Oklahoma City 4544349, Oklahoma 4544379 73104
Tulsa 4553433, Oklahoma 4544379 74146
Site Public Contact
918-505-3200
Allentown 5178127, Pennsylvania 6254927 18103
Beaver 5179446, Pennsylvania 6254927 15009
Bethlehem 5180225, Pennsylvania 6254927 18017
Carlisle 5183234, Pennsylvania 6254927 17015
Erie 5188843, Pennsylvania 6254927 16505
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Mechanicsburg 5200657, Pennsylvania 6254927 17050
New Castle 5203127, Pennsylvania 6254927 16105
Pittsburgh 5206379, Pennsylvania 6254927 15213
Site Public Contact
412-647-2811
Pittsburgh 5206379, Pennsylvania 6254927 15215
Site Public Contact
412-784-4900
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-621-2334
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
West Reading 5218867, Pennsylvania 6254927 19611
Site Public Contact
610-988-9323
Williamsport 5219585, Pennsylvania 6254927 17754
York 4562407, Pennsylvania 6254927 17408
Site Public Contact
717-724-6760
Charleston 4574324, South Carolina 4597040 29425
Greenwood 4580569, South Carolina 4597040 29646
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Dallas 4684888, Texas 4736286 75235
Dallas 4684888, Texas 4736286 75237
Dallas 4684888, Texas 4736286 75390
Fort Worth 4691930, Texas 4736286 76104
Richardson 4722625, Texas 4736286 75080
Berlin Corners 5233780, Vermont 5242283 05602
Site Public Contact
802-225-5400
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23230
Seattle 5809844, Washington 5815135 98101
Charleston 4801859, West Virginia 4826850 25304
Site Public Contact
304-388-9944
Huntington 4809537, West Virginia 4826850 25701
Antigo 5244010, Wisconsin 5279468 54409
Ashland 5244247, Wisconsin 5279468 54806
Ashland 5244247, Wisconsin 5279468 54806
Eau Claire 5251436, Wisconsin 5279468 54701
Hayward 5255882, Wisconsin 5279468 54843
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marshfield 5261969, Wisconsin 5279468 54449
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Minocqua 5263156, Wisconsin 5279468 54548
Mukwonago 5263965, Wisconsin 5279468 53149
New Richmond 5264475, Wisconsin 5279468 54017
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Rhinelander 5268720, Wisconsin 5279468 54501
Rice Lake 5268798, Wisconsin 5279468 54868
Spooner 5274034, Wisconsin 5279468 54801
Stevens Point 5274644, Wisconsin 5279468 54481
Stevens Point 5274644, Wisconsin 5279468 54482
Superior 5275191, Wisconsin 5279468 54880
Site Public Contact
701-364-6272
Waukesha 5278052, Wisconsin 5279468 53188
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT05327686
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC). The primary endpoint is nephrectomy and radiographic progression-free survival (nrPFS) with progression determined as per iRECIST criteria. SECONDARY OBJECTIVES: I. To assess the safety, toxicity and tolerability of the two treatment strategies as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5 in each treatment arm. II. To assess the objective response rate (ORR) by Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) in each treatment arm. III. Nephrectomy and radiographic progression-free survival excluding nephrectomies that were performed for non-protocol specified indications (nephrectomy and radiographic progression-free survival [nrPFS]2). IV. Radiographic progression-free survival (rPFS). V. To assess overall survival (OS) in each treatment arm. VI. To assess the time to subsequent second-line therapy or death in each treatment arm. VII. To assess the rate of cytoreductive nephrectomy in each treatment arm. VIII. To assess treatment-free survival in patients who discontinue therapy for reason other than radiographic disease progression. IX. To assess the ORR by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and iRECIST in the primary renal mass. EXPLORATORY OBJECTIVES: I. To assess composite nrPFS in the predefined histological subgroups below: Ia. Clear cell versus non-clear cell histology; Ib. International Metastatic RCC database consortium (IMDC) intermediate versus poor risk group; Ic. Systemic treatment with immunotherapy-immunotherapy combination versus immunotherapy-vascular endothelial growth factor (VEGF) targeted therapy combination; Id. Sarcomatoid versus non sarcomatoid variant. II. To identify prognostic and predictive biomarkers of response to SABR in the context of immunotherapy based treatment via assessment of tissue and blood based biomarkers. III. To evaluate the abscopal effect of SABR with systemic therapy. IIIa. Compare ORR in non-irradiated target lesions in the control arm patients undergoing immunotherapy alone to the experimental arm undergoing SABR + immunotherapy. IV. To evaluate the impact of treatment on level of inferior vena cava (IVC) thrombus. V. To compare accruing center identified iRECIST progression and centrally identified iRECIST progression events on computed tomography (CT). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib orally (PO) twice daily (BID); avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO once daily (QD); OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. ARM II: Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. After completion of study treatment, patients are followed up every 6 months for 5 years, and then annually for 3 years.